dr. André Pedro Pinto De Almeida

PhD Thesis

Functional evaluation of transcription factors in T-ALL : MYB and SOX11

André Pedro Pinto De Almeida (UGent)

(2024)

Journal Article
A1
open access

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia

André Pedro Pinto De Almeida (UGent) , Sara T'Sas (UGent) , Luca Pagliaro, Igor Fijalkowski (UGent) , Wouter Sleeckx (UGent) , Hannah Van Steenberge (UGent) , Raffaella Zamponi, Béatrice Lintermans (UGent) , Wouter Van Loocke (UGent) , Bruno Palhais (UGent) , et al.

(2024) HEMASPHERE. 8(3).

Add to list

Journal Article
A1
open access

Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy

Joana N. R. Dias, André Pedro Pinto De Almeida (UGent) , Ana S. Andre, I Aguiar, Sandra, Pedro Bule, Sara Nogueira, Soraia S. Oliveira, Belmira Carrapico, Solange Gil, Luis Tavares, et al.

(2022) SCIENTIFIC REPORTS. 12(1).

Add to list

Journal Article
A1
open access

Myb drives B-cell neoplasms and myeloid malignancies in vivo

Tim Pieters (UGent) , André Pedro Pinto De Almeida (UGent) , Sara T'Sas (UGent) , Kelly Lemeire (UGent) , Tino Hochepied (UGent) , Geert Berx (UGent) , Alex Kentsis, Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2022) BLOOD ADVANCES. 6(10). p.2987-2991

Add to list

Journal Article
A1
open access

Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia

Steven Goossens (UGent) , Anje Cauwels (UGent) , Tim Pieters (UGent) , Renate De Smedt (UGent) , Sara T'Sas (UGent) , André Pedro Pinto De Almeida (UGent) , Willem Daneels (UGent) , Pieter Van Vlierberghe (UGent) and Jan Tavernier (UGent)

(2022) HAEMATOLOGICA. 107(6). p.1448-1453

Add to list

SOX11 functions as an oncogene in Lmo2-driven T-cell lymphoblastic leukemia (T-ALL)

André Pedro Pinto De Almeida (UGent) , Tim Pieters (UGent) , Sara T'Sas (UGent) , Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2021) BLOOD. In Blood 138(Supplement 1). p.1136-1137

Add to list

Journal Article
A1
open access

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice

Tim Pieters (UGent) , Sara T'Sas (UGent) , Stijn Vanhee (UGent) , André Pedro Pinto De Almeida (UGent) , Yasmine Driege (UGent) , Juliette Roels (UGent) , Wouter Van Loocke (UGent) , Willem Daneels (UGent) , Mathijs Baens, Arnaud Marchand, et al.

(2021) JOURNAL OF EXPERIMENTAL MEDICINE. 218(10).

Add to list

Journal Article
A1
open access

MYB rearrangements and over‐expression in T‐cell acute lymphoblastic leukemia

Valentina Bardelli, Silvia Arniani, Valentina Pierini, Tiziana Pierini, Danika Di Giacomo, Paolo Gorello, Martina Moretti, Fabrizia Pellanera, Loredana Elia, Antonella Vitale, et al.

(2021) GENES CHROMOSOMES & CANCER. 60(7). p.482-488

Add to list

Journal Article
A1
open access

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies

Tim Pieters (UGent) , Sara T'Sas (UGent) , Lisa Demoen (UGent) , André Pedro Pinto De Almeida (UGent) , Lieven Haenebalcke (UGent) , Filip Matthijssens (UGent) , Kelly Lemeire (UGent) , Jinke D'Hont (UGent) , Frédérique Vanrockeghem (UGent) , Tino Hochepied (UGent) , et al.

(2019) SCIENTIFIC REPORTS. 9.

Academic Bibliography

dr. André Pedro Pinto De Almeida

Functional evaluation of transcription factors in T-ALL : MYB and SOX11

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia

Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy

Myb drives B-cell neoplasms and myeloid malignancies in vivo

Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia

SOX11 functions as an oncogene in Lmo2-driven T-cell lymphoblastic leukemia (T-ALL)

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice

MYB rearrangements and over‐expression in T‐cell acute lymphoblastic leukemia

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies

Contents

Support

Contact